Product
MORAb-202
1 clinical trial
2 indications
Indication
cancerIndication
Non-Small Cell LungClinical trial
A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior TherapiesStatus: Recruiting, Estimated PCD: 2024-03-04